Quantum BioPharma’s Licensee Unbuzzd Wellness Prepares for IPO with Audit Firm Engagement

The latest announcement is out from Quantum Biopharma ( (TSE:QNTM) ).

On May 29, 2025, Quantum BioPharma announced that its licensee, Unbuzzd Wellness Inc., formerly known as Celly Nutrition Corp., has engaged MNP LLP to conduct PCAOB audits in preparation for a potential IPO. This strategic move follows the company’s earlier steps to raise capital and explore public listing options. Unbuzzd Wellness Inc., which markets the alcohol metabolism-accelerating beverage unbuzzd, also underwent a name change effective May 23, 2025. The company’s actions are part of a broader strategy to strengthen its market position and ensure readiness for future growth opportunities.

More about Quantum Biopharma

Quantum BioPharma Ltd. is a biopharmaceutical company focused on developing innovative assets and biotech solutions for treating neurodegenerative, metabolic, and alcohol misuse disorders. The company is engaged in research and development through its subsidiary Lucid Psycheceuticals Inc., with a lead compound, Lucid-MS, targeting multiple sclerosis. Quantum BioPharma also holds a 20.11% stake in Unbuzzd Wellness Inc., which markets a beverage that accelerates alcohol metabolism.

Average Trading Volume: 8,004

Technical Sentiment Signal: Hold

Current Market Cap: C$46.23M

For an in-depth examination of QNTM stock, go to TipRanks’ Stock Analysis page.